A Phase I/II, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Pediatrics with Locally Advanced or Metastatic Solid or Primary CNS Tumors and/or who Have No Satisfactory Treatment Options

This Study is
No Longer Enrolling

Details
Age

Child

Type of Study

Treatment

Locations

Childrens Hospital Colorado

Study ID

Protocol Number: 16-0749

More information available at ClinicalTrials.gov: NCT02650401

Categories

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers